A note to all European NB community.
Hospital Sant Joan Déu is now treating patients with hu3F8 per the MSK protocol.
hu3F8 is a drug developed by MSK and manufactured by Y-mAbs
There is some discussion about 3F8 here: https://www.nbforum.org/t/immunotherapy-ch14-18-vs-antibody-3f8/11
The promise of hu3F8 is that it can be applied at significantly higher dosages than ch14:18 and 3f8 (2.5x) and is given to children as out-patients with significantly less side effects.
If anyone has any more information please post here.
My understanding is that the drug may be made available in Hong Kong and the UK soon as well.